Mary S. Jia

Mary S. Jia

Auto-generated profile, based on publicly available information

Mary S. Jia

University of Arkansas, Biomedical Engineering

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Biophysics Reviews
Verified
Journal Article
Closed access
PDF file
MPMade Harumi Padmaswari
Made Harumi Padmaswari
SAShilpi Agrawal
Shilpi Agrawal
MJMary S. Jia
Mary S. Jia
AIAllie Ivy
Allie Ivy
DMDaniel Allen Maxenberger
Daniel Allen Maxenberger
CNChristopher E E Nelson
Christopher E E Nelson
Duchene muscular dystrophy (DMD) is an X-linked neuromuscular disorder that affects about one in every 5000 live male births. DMD is caused by mutations in the gene that codes for dystrophin, which is required for muscle membrane stabilization. The loss of functional dystrophin causes muscle degradation that leads to weakness, loss of ambulation, cardiac and respiratory complications, and eventually, premature death. Therapies to treat DMD have advanced in the past decade, with treatments in clinical trials and four exon-skipping drugs receiving conditional Food and Drug Administration approval. However, to date, no treatment has provided long-term correction. Gene editing has emerged as a promising approach to treating DMD. There is a wide range of tools, including meganucleases, zinc finger nucleases, transcription activator-like effector nucleases, and, most notably, RNA-guided enzymes from the bacterial adaptive immune system clustered regularly interspaced short palindromic repeats (CRISPR). Although challenges in using CRISPR for gene therapy in humans still abound, including safety and efficiency of delivery, the future for CRISPR gene editing for DMD is promising. This review will summarize the progress in CRISPR gene editing for DMD including key summaries of current approaches, delivery methodologies, and the challenges that gene editing still faces as well as prospective solutions.

1 August 2025 in bioRxiv
Verified
Preprint
Open access
MJMary S. Jia
Mary S. Jia
MPMade Harumi Padmaswari
Made Harumi Padmaswari
LBLandon A. Burcham
Landon A. Burcham
SAShilpi Agrawal
Shilpi Agrawal
GBGabrielle N. Bulliard
Gabrielle N. Bulliard
CNChristopher E E Nelson
Christopher E E Nelson
Adeno associated virus (AAV)-mediated delivery of CRISPR associated nucleases (AAV-CRISPR) is a promising solution to treat genetic diseases such as Duchenne Muscular Dystrophy (DMD) and is now in early clinical trials. However, genotoxicity and immunogenicity concerns have hindered clinical translation. Due to the complex etiology associated with DMD, the post-transduction consequences of double-stranded breaks induced by AAV-CRISPR in disease models are unclear. This barrier is partially conferred by conventional sequencing methods where common outcomes of AAV-CRISPR editing often escape detection. However, recent reports of novel long-read sequencing approaches permit comprehensive variant detection using a broader sequence context. Here, we comprehensively investigated genomic and transcriptomic post-AAV-CRISPR transduction consequences in myoblast cells and a DMD mouse model following intramuscular and intravenous AAV-CRISPR therapy using both long- and short-read sequencing techniques. Structural variant characterization indicates that unintended on-target large insertions and inversions are common editing outcomes. We demonstrate that combining adaptive sampling with nanopore Cas9-targeted sequencing (AS-nCATS) for long-read quantification of AAV integration is synergistic for detecting difficult-to-amplify editing events. This unbiased data suggests that full-length AAV integration is equally as probable as the on-target deletion. Further, we develop a Nanopore Rapid Amplification of cDNA Ends (nRACE-seq) pipeline for long-read detection of unknown 5’ or 3’ ends of edited transcripts. The nRACE-seq approach effectively detects the presence of AAV- Dmd chimeric transcripts, erroneous splicing events, and off-target AAV integration sites. In summary, our findings offer insights into the adaptation of AAV-CRISPR DSB-mediated therapeutics for monogenic diseases and promote the standardization of CRISPR evaluation. We highlight the importance of coupling polymerase-based and polymerase-free methods in long-read sequencing to assess editing outcomes as the field progresses toward clinical applications.

19 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMade Harumi Padmaswari
Made Harumi Padmaswari
GBGabrielle N Bulliard
Gabrielle N Bulliard
SAShilpi Agrawal
Shilpi Agrawal
MJMary S Jia
Mary S Jia
CNChristopher E E Nelson
Christopher E E Nelson
Gene replacement therapies primarily rely on adeno-associated viral (AAV) vectors for transgene expression. However, episomal expression can decline over time due to vector loss or epigenetic silencing. CRISPR-based integration methods offer promise for long-term transgene insertion. While the development of transgene integration methods has made substantial progress, identifying optimal insertion loci remains challenging. Skeletal muscle is a promising tissue for gene replacement owing to low invasiveness of intramuscular injections, relative proportion of body mass, the multinucleated nature of muscle, and the potential for reduced adverse effects. Leveraging endogenous promoters in skeletal muscle, we evaluated two high-expressing loci using homology-independent targeted integration (HITI) to integrate reporter or therapeutic genes in mouse myoblasts. We hijacked the muscle creatine kinase (Ckm) and myoglobin (Mb) promoters by co-delivering CRISPR-Cas9 and a donor plasmid with promoterless constructs encoding green fluorescent protein (GFP) or human Factor IX (hFIX). Additionally, we deeply profiled our genome and transcriptome outcomes from targeted integration and evaluated the safety of the proposed sites. This study introduces a proof-of-concept technology for achieving high-level therapeutic gene expression in skeletal muscle, with potential applications in targeted integration-based medicine and synthetic biology.

3 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RBRyan M Boileau
Ryan M Boileau
SGStefan M Golas
Stefan M Golas
QMQianni Ma
Qianni Ma
BJBowen Jiang
Bowen Jiang
ARAradhana
Aradhana
ECEmma J Chory
Emma J Chory
Natural evolution is high-dimensional; organisms adapt to many pressures at once, across substrates, environments, and genetic backgrounds. Yet most directed evolution methods flatten this landscape to a single selection axis, hiding tradeoffs, and limiting what can be learned. Phage-assisted continuous evolution (PACE) is uniquely suited for multivariate selection because horizontal gene transfer couples genotype to propagation and allows the same phage lineage to traverse different selection environments. In practice, implementing this at scale has been prohibitive because each selection demands its own host culture, and every culture must be held for days to weeks within a narrow, infectable density window using continuously responsive bioreactors. In this work, TurboPRANCE is presented as an open-source, queueable robotic platform that integrates ∼200 independently controlled turbidostats with 96 parallel PACE lagoons under closed-loop control. Each turbidostat operates as a fully separate unit that can be equilibrated and initiated on its own schedule, enabling asynchronous starts and sustained operation without intervention. Automated media formulation, programmable dosing, on-deck sterilization, and adaptive scheduling coordinate growth control with the changing needs of the robotic workflow, dynamically adjusting dilution and transfer timing around formulation, sampling, and handling steps to keep each culture at consistent infectable densities despite unpredictable method demands. Cultures can be multiplexed and titrated into lagoons at defined ratios, swapped in and out on a schedule, or kept fully separate across experiments, creating a combinatorial space of selection pressures and programs that is effectively unbounded. Additionally, to enable high-throughput evolutionary tracking that scales with TurboPRANCE, Nanopore long-read sequencing was combined with DeepVariant, a deep learning-based variant caller, enabling population-level tracking of evolving variants. The result is a system that generates high-resolution time-resolvable evolutionary trajectories and large parallel datasets spanning diverse selection regimes, yielding dense, multivariate training data to map and engineer complex fitness landscapes at scale. Abstract Figure: Turbidostat, Phage, and Robotics-Assisted Near Continuous Evolution (TurboPRANCE): In phage-assisted continuous evolution (PACE), biomolecular activity is coupled to pIII expression, linking function to phage propagation. By altering the host strain, distinct selection pressures can be imposed on the same evolving phage population. In TurboPRANCE, ∼200 selection programs can vary over time, including periodic “drift” (mutagenesis), alternation between pressures, or rotational reassignment of host sources, enabling a combinatorial space of selection pressures.


16 November 2026 in bioRxiv
Verified
Preprint
Open access
RMRuqaiza Muhyudin
Ruqaiza Muhyudin
NNNicole N Noga
Nicole N Noga
FMFrancielly Morena
Francielly Morena
SHSydney Hilgenbrink
Sydney Hilgenbrink
MTMuskan Taori
Muskan Taori
NGNicholas P Greene
Nicholas P Greene
Disruption of mitochondrial dynamics and quality control precedes overt muscle wasting in cancer cachexia, but whether modulating it specifically in muscle in the presence of systemic wasting could preserve tissue mass and function remain elusive. We tested two independent, but complementary approaches in the orthotopic preclinical model of pancreatic ductal adenocarcinoma (KPC); inducing inner-mitochondrial membrane fusion through OPA1 overexpression and suppressing mitophagy via BNIP3 knockdown. Male and female C57BL/6J mice received bilateral intramuscular tibialis anterior (TA) injections of myotropic adeno-associated virus (MyoAAV) encoding murine either OPA1 cDNA or a BNIP3-targeting short hairpin RNA two weeks prior to orthotopic implantation of KPC1245 pancreatic cancer cells. Raw body and tissue weights, in vivo dorsiflexor torque and fatigability, TA fiber size and type, protein fractional synthesis rate, oxidative histochemistry, and selected molecular markers were assessed at the humane endpoint. Neither intervention prevented systemic wasting, however, in males, OPA1 overexpression partially attenuated TA mass loss, relieved torque deficits, and restored the proportion of type IIB fibers. Females developed a milder cachectic phenotype; OPA1 overexpression increased TA mass and shifted fiber composition toward type IIA fibers without any changes in torque. In males, BNIP3 knockdown markedly improved torque, restored fatigue resistance, preserved type IIB fiber proportion, and lowered DRP1 protein. Functional benefits concurred by BNIP3 shRNA delivery were accompanied by lower mixed-protein synthesis in both sexes. These findings support mitochondrial quality control as a therapeutic target while indicating that effective treatment will require calibrated, rather than maximal, suppression of mitochondrial turnover.